Cargando…

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia

Understanding how rating scale improvement corresponds to a clinical impression in patients with negative symptoms of schizophrenia may help define the clinical relevance of change in this patient population. We conducted post hoc equipercentile linking analyses of Positive and Negative Syndrome Sca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leucht, Stefan, Barabássy, Ágota, Laszlovszky, István, Szatmári, Balázs, Acsai, Károly, Szalai, Erzsébet, Harsányi, Judit, Earley, Willie, Németh, György
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785000/ https://www.ncbi.nlm.nih.gov/pubmed/30836381 http://dx.doi.org/10.1038/s41386-019-0363-2

Ejemplares similares

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
por: Demyttenaere, Koen, et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis
por: Demyttenaere, Koen, et al.
Publicado: (2022)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender
por: Sulejmanpasic, Gorana, et al.
Publicado: (2023)

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
por: Laszlovszky, I., et al.
Publicado: (2021)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study
por: Rancans, Elmars, et al.
Publicado: (2021)

S71. CLINICAL, BEHAVIOURAL AND NEURAL VALIDATION OF THE POSITIVE AND NEGATIVE SYMPTOM SCALE (PANSS) AMOTIVATION FACTOR
por: Kaliuzhna, Mariia, et al.
Publicado: (2020)

The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
por: Csehi, Reka, et al.
Publicado: (2023)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY
por: Khan, Anzalee, et al.
Publicado: (2018)

T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018)

Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire
por: Lefort-Besnard, Jérémy, et al.
Publicado: (2018)

Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review
por: Nibbio, Gabriele, et al.
Publicado: (2022)

T56. AN EXPLORATORY ANALYSIS CONVERTING SCORES BETWEEN THE PANSS AND BNSS
por: Kott, Alan, et al.
Publicado: (2018)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase
por: Vass, G., et al.
Publicado: (2021)

S48. INTER-RATER RELIABILITY OF PANSS-6 SCHIZOPHRENIA SEVERITY RATINGS OBTAINED USING THE SIMPLIFIED NEGATIVE AND POSITIVE SYMPTOMS INTERVIEW (SNAPSI)
por: Kølbæk, Pernille, et al.
Publicado: (2018)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Optimal cutoff scores of the Chinese version of 15-item negative symptom assessment that indicate prominent negative symptoms of schizophrenia
por: Zhou, Qi, et al.
Publicado: (2023)

Factor analysis of the relationship between PANSS score and family burden of patients with schizophrenia
por: Huang, Jiang, et al.
Publicado: (2021)

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence
por: Rancans, E., et al.
Publicado: (2023)

Are informants required to obtain valid ratings on the Positive and Negative Syndrome Scale (PANSS)?
por: Nielsen, Cecilie Marie, et al.
Publicado: (2023)

S244. RELIABILITY OF CORE SCHIZOPHRENIA SYMPTOMS RATINGS USING THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6) PERFORMED BY MEDICAL STUDENTS
por: Hansen, Johanna, et al.
Publicado: (2020)

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
por: Molnar, Maria Judit, et al.
Publicado: (2022)

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
por: Krekels, EHJ, et al.
Publicado: (2017)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

S49. EFFICACY OF HIGH-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ON PANSS FACTORS IN SCHIZOPHRENIA WITH PREDOMINANT NEGATIVE SYMPTOMS – RESULTS FROM AN EXPLORATORY RE-ANALYSIS
por: Hansbauer, Maximilian, et al.
Publicado: (2018)

Standardized training in the rating of the six-item positive and negative syndrome scale (PANSS-6)
por: Kølbæk, P., et al.
Publicado: (2021)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

M35. CLINICAL VALIDATION OF THE SIX-ITEM POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS-6)
por: Kølbæk, Pernille, et al.
Publicado: (2020)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials
por: Podichetty, Jagdeep T., et al.
Publicado: (2021)

Changes in neurotransmitter levels, brain structural characteristics, and their correlation with PANSS scores in patients with first-episode schizophrenia
por: Xu, Xian-Jia, et al.
Publicado: (2023)

NEGATIVE SYMPTOMS AND NEGATIVE SCHIZOPHRENIA
por: Chaturvedi, S.K., et al.
Publicado: (1984)

The Comparison of Olanzapine and Risperidone Treatment in Male Schizophrenic Patients using Positive and Negative Syndromes Scale (PANSS)
por: Lestari, Endah Tri, et al.
Publicado: (2018)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ru9ev2lp8s7hscl8d55410dh5u